Researchers have uncovered why a rare blood clotting disorder can occur after certain COVID-19 vaccines or adenovirus infections. The immune system can mistakenly target a normal blood protein (PF4) after confusing it with a viral protein. This triggers clotting in extremely rare cases. The breakthrough means vaccines can now be redesigned to avoid this reaction while staying effective.
